How should we use convalescent plasma therapies for the management of COVID-19?-Reference-Cited by-同舟云学术

How should we use convalescent plasma therapies for the management of COVID-19?

Published:2021-03-25 Issue:12 Volume:137 Page:1573-1581
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wood Erica M.¹²^ORCID,Estcourt Lise J.³⁴^ORCID,McQuilten Zoe K.¹²^ORCID

Affiliation:

1. Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia;

2. Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia;

3. Haematology/Transfusion Medicine, National Health Service (NHS) Blood and Transplant, Oxford, United Kingdom; and

4. Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

Abstract

Abstract Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/137/12/1573/1803469/bloodbld2020008903c.pdf

Reference72 articles.

1. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic;Sullivan;Transfus Med Rev,2020

2. Treatment for emerging viruses: convalescent plasma and COVID-19;Brown;Transfus Apher Sci,2020

3. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?;Garraud;Transfus Apher Sci,2020

4. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection;Hung;Clin Infect Dis,2011

5. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection;Hung;Chest,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness;Frontiers in Immunology;2024-09-09

2. The effect of convalescent plasma therapy on the rate of nucleic acid negative conversion in patients with persistent COVID-19 test positivity;Frontiers in Pharmacology;2024-08-01

3. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19;Drug Metabolism and Personalized Therapy;2023-08-24

4. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19;Drug Metabolism and Personalized Therapy;2023-08-24

5. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update;Process Biochemistry;2023-04